















## WHO RAV

### Anti-Retroviral Product List

Sr No.	Product	Dosage Form	Strengths	Reference Product	Dossier Availability
1	Abacavir	Film Coated Tablets	300 mg	Ziagen®	Available
2	Abacavir+Lamivudine+Dolutegravir	Dispersible Tablets	60+30+5 mg	Triumeq PD, GSK	Available
3	Atazanavir+Ritonavir	Tablets	300+100 mg	Reyataz® + Norvir®	Available
4	Dolutegravir (For Adult)	Tablets	10 / 25 / 50 mg	Tivicay®	Available
 5	Dolutegravir (For Paediatric)	Scored Dispersible Tablets	10 mg	Tivicay®	Available
6	Emtricitabine+Tenofovir Alafenamide	Tablets	200+25 mg	Descovy®	Available
 7	Flucytosine	Tablets	500 mg	Ancotil®	Available
 8	Lamivudine	Oral Solution	10 mg/ml	Epivir®	Available
 9	Lamivudine	Film Coated Tablets	150 mg	Epivir®	Available
 10	Lamivudine+Abacavir	Tablets	300+600 mg	Epzicom®	Available
 11	Lamivudine+Zidovudine	Film Coated Tablets	150+300 mg	Combivir®	Available
 12	Lopinavir+Ritonavir	Film Coated Tablets	100+25 / 200+50 mg	Kaletra®	Available
 13	Tenofovir	Film Coated Tablets	300 mg	Viread®	Available
 14	Tenofovir+Emtricitabine	Film Coated Tablets	300+200 mg	Truvada®	Available
 15	Tenofovir+Emtricitabine+Efavirenz	Film Coated Tablets	300+200+600 mg	Atripla®	Available
 16	Tenofovir+Lamivudine	Film Coated Tablets	300+300 mg	Epivir® + Viread®	Available
 17	Tenofovir+Lamivudine+Dolutegravir	Tablets	300+300+50 mg	Epivir® + Viread®+ Tivicay®	Available
 18	Tenofovir+Lamivudine+Efavirenz	Film Coated Tablets	300+300+400 mg	Epivir® + Viread®+ Sustiva®	Available
 19	Zidovudine	Oral Solution	10 mg/ml	Retrovir®	Available

### Upcoming Products


Sr No.	Product	Dosage Form	Strengths	Reference Product	Dossier Availability
1	Cabotegravir	Suspension for Injection	200 mg/ml	Apretud®	Q3, 2027
2	Lamivudine + Dolutegravir	Tablets	300+50 mg	Dovato® + Norvir®	Q4, 2024
3	L-Amphotericine B	Powder for Solution for Infusion	50 mg/vial	Ambisome®	Q4, 2026
4	Tenofovir Alafenamide	Tablets	25 mg	Vemlidy®	Q3, 2025

## Upcoming Products

Sr No.	Product	Dosage Form	Strengths	Reference Product	Dossier Availability
5	Tenofovir Alafenamide+Emtricitabine+ Dolutegravir	Tablets	25+200+50 mg	Vemlidy® + Descovy® + Tivicay®	Q4, 2024
6	Tenofovir Alafenamide+Emtricitabine +Rilpivirine	Tablets	25+200+25 mg	Odefsey®	Q1, 2025
7	Tenofovir Alafenamide+Lamivudine+ Dolutegravir	Tablets	25+300+50 mg	Vemlidy® + Epivir® + Tivicay®	Q3, 2025

## Under-development Products

Sr No.	Product	Dosage Form	Strengths	Reference Product
1	Bictegravir + Emtricitabine + Tenofovir Alafenamide	Tablets	30+120+15 / 50+200+25 mg	Biktarvy®
2	Cabotegravir+Rilpivirine (Kit pack)	Injection (Long acting)	400 mg/2 mL(200 mg/mL)+ 600 mg/2 mL(300 mg/mL), 600mg/3 mL(200 mg/mL)+ 900mg/3 mL(300 mg/mL)	Cabenuva Kit®
3	Darunavir+Ritonavir	Tablets	400+50 / 800+100 mg	N/A
4	Dolutegravir+Rilpivirine	Tablets	50+25 mg	Juluca®
5	Emtricitabine+Tenofovir Alafenamide	Tablets	200+25 / 200+10 mg	Descovy®
6	Lenacapavir	Injection	927 mg	Sunlenca®

 The products are WHO PQ/ERP approved

Disclaimer: "The information contained here shall not constitute an offer to sell or sale in territories where product is under patent protection."